Earnings Scheduled For February 11, 2022

  Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.

 

Companies Reporting Before The Bell

• Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.

• MISTRAS Group (NYSE:MG) is estimated to report quarterly earnings at $1.06 per share on revenue of $11.33 billion.

• IAA (NYSE:IAA) is estimated to report quarterly earnings at $0.62 per share on revenue of $500.71 million.

• Fortis (NYSE:FTS) is estimated to report quarterly earnings at $0.71 per share on revenue of $2.31 billion.

• Enbridge (NYSE:ENB) is estimated to report quarterly earnings at $0.58 per share on revenue of $8.88 billion.

• Millicom Intl Cellular (NASDAQ:TIGO) is expected to report quarterly earnings at $0.32 per share on revenue of $1.70 billion.

• CAE (NYSE:CAE) is expected to report quarterly earnings at $0.19 per share on revenue of $918.24 million.

• Neurocrine Biosciences (NASDAQ:NBIX) is projected to report quarterly earnings at $0.52 per share on revenue of $316.79 million.

• Genpact (NYSE:G) is projected to report quarterly earnings at $0.46 per share on revenue of $911.92 million.

• Apollo Global Management (NYSE:APO) is likely to report quarterly earnings at $1.10 per share on revenue of $1.15 billion.

• Under Armour (NYSE:UAA) is projected to report quarterly earnings at $0.07 per share on revenue of $1.47 billion.

• GreenPower Motor Co (NASDAQ:GP) is projected to report earnings for its third quarter.

• Newmark Group (NASDAQ:NMRK) is expected to report quarterly earnings at $0.56 per share on revenue of $876.23 million.

• Magna International (NYSE:MGA) is expected to report quarterly earnings at $1.59 per share on revenue of $9.31 billion.

• Byrna Technologies (NASDAQ:BYRN) is estimated to report quarterly loss at $0.05 per share on revenue of $10.85 million.

• Sylvamo (NYSE:SLVM) is estimated to report quarterly earnings at $1.26 per share on revenue of $962.13 million.

• Green Plains Partners (NASDAQ:GPP) is estimated to report earnings for its fourth quarter.

• Essent Gr (NYSE:ESNT) is likely to report quarterly earnings at $1.40 per share on revenue of $241.13 million.

• Proto Labs (NYSE:PRLB) is estimated to report quarterly earnings at $0.27 per share on revenue of $117.36 million.

• W.P. Carey (NYSE:WPC) is likely to report quarterly earnings at $0.52 per share on revenue of $328.22 million.

• Sensient Technologies (NYSE:SXT) is expected to report quarterly earnings at $0.72 per share on revenue of $341.27 million.

• Cleveland-Cliffs (NYSE:CLF) is expected to report quarterly earnings at $2.12 per share on revenue of $5.73 billion.

• Bruker (NASDAQ:BRKR) is projected to report quarterly earnings at $0.58 per share on revenue of $663.88 million.

• Newell Brands (NASDAQ:NWL) is expected to report quarterly earnings at $0.32 per share on revenue of $2.65 billion.

• Dominion Energy (NYSE:D) is expected to report quarterly earnings at $0.91 per share on revenue of $4.15 billion.

• American Axle & Mfg Hldgs (NYSE:AXL) is projected to report quarterly earnings at $0.02 per share on revenue of $1.28 billion.

• Ares Management (NYSE:ARES) is estimated to report quarterly earnings at $0.72 per share on revenue of $629.08 million.

• Goodyear Tire & Rubber (NASDAQ:GT) is likely to report quarterly earnings at $0.32 per share on revenue of $4.96 billion.

• Under Armour (NYSE:UA) is projected to report earnings for its fourth quarter.

• AllianceBernstein Holding (NYSE:AB) is estimated to report quarterly earnings at $1.00 per share on revenue of $966.91 million.

• Green Plains (NASDAQ:GPRE) is estimated to report quarterly earnings at $0.26 per share on revenue of $755.55 million.

• Tyme Technologies (NASDAQ:TYME) is expected to report earnings for its third quarter.

• Dominion Energy (NYSE:DCUE) is likely to report earnings for its fourth quarter.

 

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

AZN